Topic
diabetes
Manufacturing Pharmaceuticals #novo nordisk#eli lilly
Ozempic-maker Novo Nordisk sues Eli Lilly for false advertising over weight-loss drug claims
Novo Nordisk has sued Eli Lilly, alleging false advertising in Eli Lilly's campaigns that compare weight-loss and diabetes drugs. Novo claims Eli Lilly intentionally used outdated studies and omitted higher-dose options to create a misleading impression of superiority. The lawsuit seeks to pull the ads and run corrective advertising.
Jul 21, 2026 1 source
Manufacturing Pharmaceuticals #semaglutide#excess stock
Semaglutide therapy market faces Rs 100 crore excess stock after initial rush
The Indian semaglutide therapy market is facing an excess stock of approximately Rs 100 crore, with stockists holding 50-60 days of inventory after a sharp slowdown in May sales. The market had surged following patent expiry in March but growth slowed drastically, leading to a halt in fresh procurement from pharmaceutical companies.
Jun 22, 2026 1 source
Regulations & Compliance Product Standards #medicine#price cap
Price Caps Imposed on 30 Medicines
Read the full story for in-depth analysis.
Jun 1, 2026 1 source